Navigation Links
MU cancer scientists form new company with international pharmaceutical firm
Date:12/2/2010

esearch Reactor, the most powerful university reactor in the world, is one of only a few sites able to produce the radioactive gold nanoparticles created by Katti and Kannan.

"MU's proactive support of our research has allowed Dr. Kannan and I to join Shasun in taking this important step toward helping cancer patients," Katti said. "This kind of culture has put MU on the map as a destination for world-class science that attracts international attention and investment."


'/>"/>

Contact: Laura Gerding
gerdingla@health.missouri
573-882-9193
University of Missouri School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scientists propose new international cancer effort akin to Human Genome Project
2. U of I scientists develop tool to trace metabolism of cancer-fighting tomato compounds
3. New strategies for cancer drug development urgently needed
4. MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors
5. The most aggressive forms of breast cancer elude cellular control mechanisms in order to expand
6. New imaging technique accurately finds cancer cells, fast
7. In the test tube, teams reconstruct a cancer cells beginning
8. Businessman-philanthropist assists TGen-VARI study of rare cancer
9. UGA researchers identify key enzyme that regulates the early growth of breast cancer cells
10. American Association for Cancer Research hosts 102nd annual meeting in 2011
11. Never-smokers fare far better than smokers after radiation therapy for head and neck cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... extinct in Europe 24,000 years ago, but until now the ... mitochondrial DNA sequences from 17 new fossil samples, and compared ... the decline of the cave bear started 50,000 years ago, ... change. "The decline in the genetic diversity of the ...
... University researcher has helped to locate and identify a gene ... terriers. This same gene may be responsible for a similar ... improved screening and diagnosis of the disease in dogs and ... both canines and humans. Dr. Natasha Olby, associate professor ...
... Spanish . A study led ... suggests that a water soluble extract of cinnamon, which ... with diabetes and heart disease. The ... Human Nutrition Research Center (BHNRC) operated by USDA,s ...
Cached Biology News:True causes for extinction of cave bear revealed 2Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans 2Researchers study cinnamon extracts 2
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... (Nasdaq: SQNM ) is very pleased to ... 2011;342:c7401) of a groundbreaking international study led by our ... of Hong Kong. Building on early work from the ... of a large-scale clinical study that validates a noninvasive, ...
... MAR, Calif., Jan. 12, 2011 iDiverse today announced that ... Scientific Advisory Board. "We are extremely pleased to ... John Burr, president and CEO of iDiverse. "Dr. Miller has ... commercialization of novel bio-based technologies that have greatly improved the ...
... SeqWright Inc., a world-wide leader in custom genomic ... strides to position itself as the Next-Generation Sequencing ... can be attributed to the company,s ability to ... in key genomics technologies. Building on this success, ...
Cached Biology Technology:Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal 2Carl A. Miller, PhD, Joins iDiverse's Business and Scientific Advisory Board 2SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2